Oxana P. Trofimova

Oxana P. Trofimova

Auto-generated profile, based on publicly available information

Oxana P. Trofimova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2021 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
LZLiudmila Zhukova
Liudmila Zhukova
IAIuliia I. Andreeva
Iuliia I. Andreeva
LZLarisa E. Zavalishina
Larisa E. Zavalishina
AZAziz D. Zakiriakhodzhaev
Aziz D. Zakiriakhodzhaev
IKIrina A. Koroleva
Irina A. Koroleva
НАНевольских Алексей Алексеевич
Невольских Алексей Алексеевич
Breast cancer (BC) is a malignant tumor originating from the epithelium of the breast tissue. There is no single etiological factor in the development of breast cancer. In 310% of patients with breast cancer, the development of the disease is associated with the presence of mutations in the breast cancer gene (BRCA) 1, BRCA2, CHEK, NBS1, TP53. In other patients, breast cancer is sporadic.

30 November 2020 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
AHA. Hofmann
A. Hofmann
MAM. Aapro
M. Aapro
TFT. A. Fedorova
T. A. Fedorova
YZYe. B. Zhiburt
Ye. B. Zhiburt
ASA. V. Snegovoy
A. V. Snegovoy
IPI. V. Poddubnaya
I. V. Poddubnaya
The huge global burden of oncological diseases is growing and measures to counter this complex challenge are high on national health agendas. The Russian National Long-Term Oncology Strategy 2030 defines priorities, goals and directions in the fight against cancer. Italso contains action plans for more effective prevention, earlier and more specific diagnosis and more effective treatment options. Against this backdrop, experts now suggest to complement standard oncology treatment strategies by adding Patient Blood Management (PBM). For many clinical disciplines where a low blood count and considerable blood loss are commonly encountered, this bundle of care is the new standard. Based on clinical and scientific evidence, it aims to optimise medical and surgical patient outcomes by clinically managing and preserving a patients blood. The principles of this comprehensive concept can and must be transferred to oncology, thus offering value in improving cancer care and the efficacy of medical institutions. Accumulating evidence demonstrates that anaemia and iron deficiency, but also thrombocytopenia, blood loss and coagulopathy are independent risk factors for adverse patient outcomes including morbidity, mortality, reduced quality of life and prolonged average length of hospital stay in both surgical and medical patients. For the timely and effective detection and correction of these risk factors, an international network of multi-disciplinary clinicians and researchers has developed PBM. The rapidly growing body of evidence for PBM not only shows improved patient outcomes, but also reduced resource utilisation including the use of allogeneic blood components. The reduction of allogeneic blood transfusion further improves patient safety and outcomes, since transfusion is another independent risk factor for adverse outcomes. Supported by WHO endorsements and following the recommendations of an increasing number of state or national health authorities, PBM is about to become a new standard of care. However, even though the aforementioned risk factors are highly prevalent in oncology settings due to chemo-/radiotherapy and the pathology of the disease, the integration of PBM in standard oncology treatment pathways is lagging behind. Thus, and in support of the Russian National Long-Term Oncology Strategy 2030 to improve quality of oncological care, with the support of the National Association of Specialists in PBM (NASPBM), the PBM Oncology Working Group of the Russian Federation was created, consisting of national and international experts in oncology and PBM. On July 9, 2020, the Working Group met to discuss the rationale for PBM in oncology and to assess the need to implement PBM in Russian oncology care. As a result, the Group recommended to include PBM as an integral part of standard oncology treatment pathways, delineated the action required from facilitating stakeholders in the Russian Federation, determined a roadmap for implementation and developed a national resolution as a call to action on the matter. Presented herein, this resolution acknowledges the global and local impetus to reduce cancer mortality, and the rationale for PBM interventions to improve patient outcomes and alleviate the social and economic burden of cancer on the healthcare system.

21 February 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
DBDaiana A. Balaeva
Daiana A. Balaeva
DRDenis Romanov
Denis Romanov
OTOxana P. Trofimova
Oxana P. Trofimova
ZGZarina Z. Gadzhibabaeva
Zarina Z. Gadzhibabaeva
YGYury Yu. Gorchak
Yury Yu. Gorchak
ГАГаряев Гаря Анатольевич
Гаряев Гаря Анатольевич
In modern medicine, radiation therapy (RT) is one of the main therapies for cancer. According to the World Health Organization, about 70% of patients diagnosed with cancer require RT at some stage of treatment. Development and improvement of methods for early diagnosis of cancers, multimodal therapy for cancer patients, including surgical intervention, new drug treatment regimens, modern methods of conformal 3D-RT and proton therapy significantly improved the treatment outcomes of patients and increased their life expectancy. Modern RT is a high-tech chain of sequential use of complex technical devices and mathematical calculations to destroy the tumor without adversely affecting the surrounding normal tissues. Some patients develop radiation injuries to normal organs and tissues that reduce their quality of life. Prevention and treatment of such injuries are urgent problems of modern oncology. The article addresses the pathogenesis and mechanism of the development of systemic and local radiation responses, as well as methods of treatment and prevention of some of them. Three electronic databases, including PubMed, Cochrane and EMBASE, and Russian radiotherapists' publications, were used for systematic review in the information retrieval process.

29 June 2023 in Medical alphabet
Verified
Journal Article
Open access
PDF file
ETE. V. Timoshkina
E. V. Timoshkina
STS. I. Tkachev
S. I. Tkachev
VGV. V. Glebovskaya
V. V. Glebovskaya
ОТО. П. Трофимова
О. П. Трофимова
MCM. V. Chernykh
M. V. Chernykh
SIS. M. Ivanov
S. M. Ivanov
Hypofractionated radiotherapy in the treatment of breast cancer patients has a signifiant advantage over conventional fractionation due to the shorter duration of treatment course while maintaining its antitumor effiacy. Usage of hypofractionated regimens may be restricted in patients with immediate breast reconstruction because of higher rate of complications. The aim of this study is to evaluate the incidence of complications in the reconstructed breast after hypofractionated radiotherapy. The study involved 100 patients with breast cancer after immediate implant-based breast reconstruction who underwent an adjuvant course of external beam radiation therapy with a single dose of 2.67 Gy to a total dose of 40.05 Gy. In our study the incidence of capsular contracture is 8 %, infectious complications – 2.3 %, protrusion – 4.6 %. The total incidence of complications is 15 %, which does not exceed the incidence in conventional fractionation.

22 January 2025 in Voprosy onkologii
Verified
Journal Article
Open access
ВСВладимир Федорович Семиглазов
Владимир Федорович Семиглазов
ПКПетр Владимирович Криворотько
Петр Владимирович Криворотько
ТСТатьяна Юрьевна Семиглазова
Татьяна Юрьевна Семиглазова
ЕАЕлена Владимировна Артамонова
Елена Владимировна Артамонова
АААнна Сергеевна Артемьева
Анна Сергеевна Артемьева
ЮШЮлиана Сергеевна Шатова
Юлиана Сергеевна Шатова
В статье представлены результаты голосования I Cанкт-Петербургского международного консенсуса по диагностике и лечению рака молочной железы «Белые ночи 2024», посвященного наиболее актуальным и спорным вопросам диагностики, хирургической тактики, лучевой терапии и системного лечения данной категории пациентов. Под председательством член-корреспондента РАН, профессора Владимира Федоровича Семиглазова в международном консенсусе приняли участие 38 экспертов в области диагностики и лечения рака молочной железы (РМЖ), проголосовавших в ходе прямого эфира по 32 вопросам, разделенным на блоки раннего и метастатического РМЖ. Проведение II Cанкт-Петербургского международного консенсуса по диагностике и лечению РМЖ «Белые ночи 2025» запланировано со 2 по 5 июля 2025 года.

1 January 2025 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
AAArman Vachakanovich Arakelyan
Arman Vachakanovich Arakelyan
GTG. S. Tumyan
G. S. Tumyan
ASA. A. Semenova
A. A. Semenova
MKM. Yu. Kichigina
M. Yu. Kichigina
IZI. Z. Zavodnova
I. Z. Zavodnova
ЮКЮ. И. Ключагина
Ю. И. Ключагина
AIM. To determine the optimal strategy of chemotherapy for patients with relapsed/refractory (r/r) primary mediastinal (thymic) large B-cell lymphoma (PMBCL). MATERIALS & METHODS. The study is based on the clinical data from 26 patients with r/r PMBCL treated at the NN Blokhin National Medical Cancer Research Center from 2010 to 2024. The patients were 20–48 years of age (median 33 years); there were 21 (81 %) women. All patients had a bulky mediastinal tumor mass (> 10 cm in maximum dimension). RESULTS. All calculations were performed in the combined group (n = 26) which included patients with both primary refractory PMBCL (n = 21) and tumor relapses (n = 5). Refractoriness was confirmed by PMBCL progressing within less than 6 months from the completion of the first therapy program. Relapses developed during 2 years after the first-line therapy. The treatment of r/r PMBCL included the R-DHAP, R-ICE, R-BeGeV, and R-B protocols. In 24 out of 26 patients, the second- or subsequent-line salvage therapy programs included immune checkpoint inhibitor (CPI; nivolumab or pembrolizumab) and immunoconjugate (brentuximab vedotin, BV) boosts. CPIs were received by 11 (42 %) patients, and CPI + BV were administered to 13 (50 %) patients. With the follow-up median of 28 months in the total group of r/r PMBCL patients (n = 26), the 3-year progression-free survival (PFS) was 41.7 % (median 14 months), whereas the 3-year overall survival (OS) was 73.7 % (median not reached). Radiotherapy (RT) was administered to 11 (42 %) patients. The RT recipients showed the 3-year PFS of 72.7 % and OS of 100 % as compared to non-recipients with 20.3 % and 56.3 %, respectively. Autologous hematopoietic stem cell transplantation (auto-HSCT) was performed in 12 (46 %) patients. Auto-HSCT recipients showed the 3-year OS of 100 % as compared to non-recipients with 51 %. CONCLUSION. This study demonstrated that new drugs, in particular CPI ± BV, added to the second- and subsequent-line salvage therapy protocols in r/r PMBCL can be used to overcome the primary tumor refractoriness and neutralize this extremely unfavorable factor. High-dose chemotherapy (conditioning) with subsequent auto-HSCT is clearly associated with the best long-term survival rates. By the time of drafting this paper, 12 followed-up auto-HSCT recipients remained tumor-free. In cases of RT infeasibility at the initial stage, it was mediastinal radiation in the therapy for r/r PMBCL which showed its crucial prognostically favorable value and led to considerable improvement of PFS and OS rates. In general, the capacity of chemotherapy for patients with r/r PMBCL includes CPI ± BV-boosted salvage therapy protocols as well as added auto-HSCT and RT.